Nectar Life Sciences Assembles Business Advisory Board of Consumer Goods and Health Services Industry Titans to Drive Business Expansion
12 Jun 2023
Executive Change
NEW YORK--(BUSINESS WIRE)--Nectar Life Sciences, an allergy-focused healthcare holding company, announced today that they added four business experts to their business advisory board. Nectar Life Sciences is changing how we treat allergies and their associated conditions through an evidence-based, comprehensive allergy treatment program that provides patients long-term relief from their allergies.
'Nectar\u2019s Business Advisory Board is a validation of our commitment to excellence and to reinvent allergy care.'
The board is comprised of leaders in consumer products, health services, and patient advocacy industries. Their goal is to advise Nectar on how to most effectively bridge best-in-class business practices with the highest quality healthcare.
“We are excited to partner with these leading executives, who each bring a unique perspective and expertise to one or more strategic initiatives,” said Dr. Kenneth Chahine, Founder and CEO of Nectar. “Nectar’s Business Advisory Board is a validation of our commitment to excellence and to reinvent allergy care.”
Nectar’s new business advisory board is made up of an established group of seasoned executives with decades of relevant experience between them. Members of the business advisory board include:
Andy Grover: Andy is the Co-Founder and Chief Development Officer at Tend, the dental brand bringing a hospitality mindset to oral health. With over 15 years of real estate, healthcare, and branding experience, Andy is a leader committed to creating safe, holistic environments and consumer-friendly healthcare models tailored specifically to meet patients’ needs and emotions.
David Jaffe: David is the Chair of the Board of the Directors at Food Allergy Research & Education (FARE), the largest private funder of food allergy research. David has been a lifelong advocate for research and education initiatives to help the 32 million Americans with Food Allergies. David has held numerous C-level leadership roles throughout his retail career and is an angel investor and advisor to early-stage entrepreneurs.
Thomas Lee: Tom is the Chairman, Founder, and former CEO of One Medical Group, a membership-based primary care practice on a mission to make getting quality care more affordable, accessible, and enjoyable for all through a blend of human-centered design, technology, and an exceptional team. With over two decades of healthcare experience, Tom is an expert on medical practice redesign, health information technology, and mobile application design.
Eric Ryan: Eric is a designer, marketer, and co-founder of three globally recognized brands: Method Products, a brand focused on creating non-toxic biodegradable cleaning products, Olly, a gummy vitamin and supplement brand, and Welly Health, maker of the finest fabric bandages and ointments. For the last 20 years, Eric has built global brands rooted in innovative design and sustainability.
About Nectar
Nectar is changing how we treat America’s #1 chronic condition with Nectar Allergy Drops. We achieve life-long allergy relief through clinically backed, industry-proven immunotherapy drops and a data-driven, tech-focused, hybrid virtual/physical patient care experience. Nectar’s personalized immunotherapy allergy drops are to be taken sublingually (administered under the tongue), address the root cause of allergies, and are an alternative to inconvenient allergy shots and the temporary relief from antihistamines.
For more information, visit MyNectar.com or follow us on Instagram and Facebook.
About Nectar Life Sciences
Nectar Life Sciences, an allergy-focused healthcare holding company, is building a comprehensive, vertically integrated allergy healthcare platform that leverages data and clinical research to offer a personalized, patient-centric approach to allergy care. Led by a team of seasoned healthcare executives and innovators, the company’s mission is to educate allergy sufferers about innovative treatment options, positively transform their treatment experience, and broadly increase access to life-changing allergy treatment.
For more information, visit Nectar Life Sciences or follow us on LinkedIn.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.